Healthcare AI patent filings now point beyond radiology into clinical workflows, robotic surgery, haptics, and surgical navigation. Patent data shows where the durable layer is forming.
Healthcare AI is not the loudest AI market. It may be the most durable one.
The public conversation still treats healthcare AI as a radiology story, or a debate about whether models will replace clinicians. The patent data points somewhere more interesting. The real boom is not just diagnostic software. It is the operating layer around imaging, pathology, ultrasound, robotic surgery, patient data, clinical workflow, and decision support.
That matters because healthcare is not a clean software market. It is regulated, institution-heavy, data-constrained, and workflow-bound. Those are exactly the conditions where patent strategy starts to matter. When a product has to fit into the way clinicians already work, the defensible invention is rarely just the model. It is the data pipeline, the modality-specific workflow, the human interface, and the way the system turns clinical context into a usable action.
We pulled the healthcare AI landscape across AI applied to medical imaging, radiology, pathology, diagnostic ultrasound, and adjacent clinical analytics. The result was 49,263 patent families published since 2015.
The curve is hard to ignore: 172 families in 2015, 11,607 in 2025, and 2026 pacing toward another large year. That is about 67 times growth in a decade.
This is why healthcare AI feels quieter than foundation models but may become more economically important. A general-purpose model can get copied, compressed, fine-tuned, or wrapped by a larger platform. A healthcare AI workflow has to survive messy clinical data, modality constraints, reimbursement reality, hospital procurement, and patient-specific edge cases. The patent activity is following that complexity.
The top of the portfolio data does not look like a startup leaderboard. It looks like healthcare infrastructure.
Philips leads the landscape with 2,734 families. That is more than Siemens AG at 1,520 and GE Healthcare at 897 combined. Together, the legacy imaging vendors hold more than 5,500 filings in this slice of healthcare AI.
That is the first strategic lesson. The incumbents are not sitting still while AI companies move around them. They are absorbing the AI layer into the installed base: scanners, imaging workstations, clinical workflows, hospital relationships, service contracts, and regulatory experience.
The standout newer name is Tempus AI, with 437 families. For a company that went public in mid-2024, that is a serious patent footprint. Many healthcare AI startups have strong science, strong data stories, and strong investor narratives. Far fewer have a visible patent position that shows up at this scale.
The geographic split is just as important as the company leaderboard. China accounts for 21,904 of the 49,263 families in this landscape, about 44 percent of global filings. That is more than the United States, Europe, and Japan combined.
Shanghai United Imaging Healthcare alone appears with 313 families. For US buyers, investors, and strategic teams, this matters because the patent environment around healthcare AI is not just domestic. A US startup can look differentiated inside a US investor deck and still be building inside a global filing field that is already crowded in important modalities.
That does not mean every filing is equally valuable. It does mean the competitive map is wider than the usual US venture lens. Any serious assessment of healthcare AI now has to account for the Chinese filing base, especially in imaging hardware, image interpretation, and workflow integration.
Healthcare AI also breaks one of the lazier AI narratives. The story is not simply that models replace workers.
In 2016, Geoffrey Hinton famously suggested that people should stop training radiologists because deep learning would outperform them within five years. That prediction did not land. Mayo Clinic’s radiology staff has grown since 2016. The American College of Radiology has reported growth in the number of practicing US radiologists, and long-term workforce projections still point to rising demand.
The broader healthcare labor picture is even more strained. Physician and nursing shortages are not small operational annoyances. They are structural constraints. Imaging volume, pathology demand, patient data complexity, and documentation burden are all rising faster than the clinical workforce can comfortably absorb.
That is why the patent boom matters. AI in this market is not just a replacement technology. It is capacity infrastructure. The valuable systems help clinicians handle more complexity with better context, fewer handoffs, and less waste. The patent filings are starting to show where companies think that productivity layer will be built.
The most interesting healthcare AI work is not always visible in the public-company leaderboard. A smaller portfolio can reveal where the frontier is moving before the market narrative catches up.
As a quick example, we ran a Minesoft Origin search for IX Innovation. An exact assignee search for IX Innovation returned 92 application-grouped patent records. A combined IX Innovation plus John Cronin or Seth Cronin inventor search returned 79 records. Several of those public records list ipCapital Group team members John Cronin and Seth Cronin as inventors, alongside Jeffrey Roh, Justin Esterberg, Michael Baker, and others.
That cluster is not a generic “AI in healthcare” story. It is much more specific. Representative publications include:
The pattern is important. These are not simply “AI diagnosis” filings. They sit closer to surgical execution: navigation, simulation, haptics, robotic control, patient-specific planning, and clinician-machine interface. In classification terms, the IX Innovation search concentrated heavily in A61B surgical and diagnostic technology and G16H healthcare informatics, with additional signals in G06N machine learning and G06T image processing.
That is where the healthcare AI market starts to look less like a software category and more like a systems category. The model matters, but so does the operating room context. The data matters, but so does the surgeon interface. The simulation matters, but so does the robot’s ability to translate a plan into a safe sequence of actions for a specific patient.
The practical lesson is not that every healthcare AI company needs a huge portfolio. It is that the valuable patent work has to be attached to the real clinical bottleneck.
For a radiology company, that may be modality-specific image interpretation, training data curation, report generation, or integration into the reading workflow. For pathology, it may be tissue preparation, image normalization, annotation, and diagnostic triage. For robotic surgery, it may be navigation, haptics, surgical planning, simulation, end-effector control, and handoff between human and autonomous operation.
That is a different mindset from filing broad claims around “AI for healthcare.” The stronger strategic question is: where does the system convert messy clinical reality into a repeatable action that the market actually needs?
Healthcare AI is no longer an emerging corner of the patent system. It has a clear top tier in imaging, a credible venture-scale challenger in Tempus, a major China filing base, and a growing set of workflow-specific portfolios around surgery and clinical operations.
The companies that win the next decade will not be the ones that merely announce AI capability. They will be the ones that turn clinical workflows into owned technical positions: the image pipeline, the surgical interface, the planning engine, the patient-specific simulation, the documentation layer, and the operational loop that makes clinicians more productive.
This analysis is for strategic planning purposes and does not constitute legal advice. Patentability, infringement, validity, and clearance questions should be reviewed with qualified patent counsel.
Need to understand what this means for your portfolio? ipCapital Group helps leadership teams turn patent landscapes into practical decisions about filing strategy, competitive diligence, M&A readiness, and monetization.
Start a conversation with ipCapital Group or download the IP Strategy Playbook.
Work with ipCapital Group
From invention to monetization, our team has guided 2,000+ engagements across the full IP lifecycle. Start with a free 30-minute discovery call.
Written by
Seth Cronin